Kythera Biopharmaceuticals Releases Second Quarter 2014 Operating Results


The following excerpt is from the company's SEC filing.

Westlake Village, Calif., August 7, 2014 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for its second quarter 2014 and provided an update on recent accomplishments.

“We made significant progress during the second quarter, including the submission of our New Drug Application for ATX-101. The FDA has determined the application is sufficiently complete to permit a substantive review, and provided a PDUFA date of May 13, 2015. If approved, ATX-101 will be the first non-surgical treatment for the reduction of submental fat,” said Keith Leonard, KYTHERA’s President and CEO. “A dditionally, we plan to make multiple ex-U.S. regulatory submissions by the second quarter of 2015.”

Cash, cash equivalents and marketable securities totaled $134.7 million at June 30, 2014. This compares to $75.7 million, including $11.1 million of restricted cash at June 30, 2013. The Company had net use of cash, cash equivalents and marketable securities of $16.7 million in the second quarter and, based on current operating plans, believes its existing cash, cash equivalents and marketable securities will allow it to fund its operating plan through at least the next 12 months. Given anticipated activities in the remainder of the year, the Company expects to end 2014 with a year-end cash balance of between $90 million and $100 million.

Research and development expenses totaled $11.0 million for the second quarter 2014 and $20.9 million for the first half of 2014, compared to $7.8 million for the second quarter 2013 and $17.8 million for the first half of 2013. The increase in research and development expenses over the same period last year is primarily attributable to higher costs from an increase in headcount and related personnel costs, increased external costs related to previously announced additional trials initiated in 2014, NDA filing preparations and the building of a new medical affairs function.

  General and administrative expenses totaled $7.4 million for the second quarter of 2014 and $13.5 million for the first half of 2014, compared to $4.0 million for the second quarter of 2013 and $7.7 million for the first half of 2013. The increase in general and administrative expenses in 2014 compared to the similar period in 2013 is primarily due to personnel costs associated with an increase in headcount, increased external costs associated with preparations for potential launch of ATX-101, and increased costs as a result of maintaining a growing public company.   GAAP Net loss was $19.5 million for the second quarter of 2014, compared to $12.3 million for the second quarter of 2013.   Key Second Quarter Accomplishments   ·                  In May 2014, KYTHERA submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ATX-101 (deoxycholic acid) as an injectable treatment for the reduction of submental fat.   ·                  Subsequent to the end of the quarter, the Company announced that the NDA for ATX-101 was accepted for filing by the FDA. The acceptance of the NDA reflects the FDA’s determination that the application is sufficiently complete to permit a substantive review. The NDA will be subject to a standard review and will have a Prescription Drug User Fee Act (PDUFA) action date of May 13, 2015. The PDUFA date is the goal date for the FDA to complete its review of the NDA. In addition, the FDA has informed the company that the FDA’s Division of Dermatology and Dental Products is currently planning to hold an Advisory Committee meeting on the ATX-101 application during the review.   Conference Call   KYTHERA will hold a conference call this afternoon, August 7, at 4:30 p.m. ET, to discuss results from its quarter ended June 30, 2014. The conference call will be simultaneously webcast on the Company’s web site at www.kytherabiopharma.com, and archived for future review. Dial-in numbers for the conference call are as follows: U.S. participants (877) 344-3890, international participants (760) 666-3770, passcode: 82140236.  

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA’s product candidate, ATX-101, is currently in late-stage clinical development for the reduction of submental fat, which commonly presents as a double chin, and is a potential first-in-class submental contouring injectable drug. KYTHERA submitted its New Drug Application for ATX-101 in May 2014, which the FDA has determined is sufficiently complete to permit a substantive review. KYTHERA also maintains an active research interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at www.kytherabiopharma.com.

  KYTHERA BIOPHARMACEUTICALS, INC. CONDENSED CONSOLIDATED FINANCIAL RESULTS (in thousands, except per share amounts) (unaudited)       Three Months Ended June 30,   Six Months Ended June 30,       2014   2013   2014   2013                       Operating expenses:                   In-process research and development   $ —   $ —   $ 52,757   $ —   Research and development   10,962   7,767   20,942   17,801   General and administrative   7,364   3,973   13,485   7,698   Total operating expenses   18,326   11,740   87,184   25,499   Loss from operations   (18,326 ) (11,740 ) (87,184 ) (25,499 ) Interest income   51   35   118   63   Interest expense   (1,207 ) (553 ) (1,861 ) (948 ) Net loss   $ (19,482 ) $ (12,258 ) $ (88,927 ) $ (26,384 ) Per share information:                   Net loss, basic and diluted   $ (0.86 ) $ (0.67 ) $ (4.00 ) $ (1.44 )                     Basic and diluted weighted average shares outstanding   22,660,000   18,423,000   22,250,000   18,379,000     CONDENSED CONSOLIDATED BALANCE SHEET DATA (in thousands)       June 30,   December 31,       2014   2013       (unaudited)       Assets           Cash and cash equivalents, marketable securities and restricted cash   $ 134,688   $ 172,120   Working capital   123,023   155,695   Total assets   138,758   173,407   Notes payable (current and noncurrent)   30,622   11,505   Common stock and additional paid-in capital   360,628   322,052   Total stockholders’ equity   99,492   149,839    

  RECONCILIATION OF GAAP TO NON-GAAP NET LOSS (in thousands) (unaudited)       Six Months Ended June 30,       2014   2013               Net loss — GAAP   $ (88,927 ) $ (26,384 ) In-process research and development   52,757   —   Net loss — Non-GAAP   $ (36,170 ) $ (26,384 )   Investor Contact: Heather Rowe, Director, Investor Relations Tel: (818) 587- 4559 hrowe@kytherabiopharma.com    

The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here. KYTHERA Biopharmaceuticals next reports earnings on August 07, 2014.

To receive a free e-mail notification whenever KYTHERA Biopharmaceuticals makes a similar move, sign up!

Other recent filings from the company include the following:

KYTHERA Biopharmaceuticals's Chief Financial Officer just cashed-in 375 options - Nov. 20, 2014
Kythera Biopharmaceuticals Releases Third Quarter 2014 Operating Results - Nov. 10, 2014
KYTHERA Biopharmaceuticals Just Filed Its Quarterly Report: 9. Basic and Dilu... - Nov. 10, 2014
KYTHERA Biopharmaceuticals Just Received a Notice of Effectiveness - Nov. 6, 2014
Registration statement under Securities Act of 1933 - Nov. 6, 2014

   Auto Refresh

Feedback